Paul Freemont

Paul Freemont – Co-Director

SynbiCITE

http://www.synbicite.com/

Professor Paul Freemont is co-director and co-founder of the EPSRC Centre for Synthetic Biology and Innovation (since 2009) and the National UK Innovation and Knowledge Centre for Synthetic Biology (SynbiCITE; since 2013) at Imperial College London. He was previously the Head of the Division of Molecular Biosciences (2005-2012), Head of the Imperial College Centre for Structural Biology (2000-2005) having joined Imperial from Cancer Research UK London Research Institute. His research interests span from understanding the molecular mechanisms of human diseases to the development of synthetic biology platform technologies and biosensors and is the author of over 160 peer-reviewed scientific publications. He also holds a number of external positions including vice-chair of the Diamond Light Source Scientific Advisory Committee and member of MRC Molecular and Cellular Medicines Board. He has previously held positions including membership of UK Synthetic Biology Roadmap Coordination Group (2011-2012), Royal Academy of Engineering enquiry into Synthetic Biology (2006-2008); member of Cancer Research UK Biological Sciences funding panel (2006-2011); member of Wellcome Trust Genes Molecules and Cells funding panel (2002-2005). Professor Freemont is a co-founder of the spin out company Equinox Pharma Ltd and sits on the Scientific Advisory Board of Netscientific Ltd and has held consultancies with a number of other companies and organisations including Scottish Enterprise, Syngenta and Rio Tinto. He has also been active in a number of public engagement activities including the RCUK Public Dialogue on Synthetic Biology (2010) and the Royal Academy of Engineering public engagement on synthetic biology (2008). Along with Prof. Kitney, he has appeared regularly on radio and television broadcasts on the subject of synthetic biology and has successfully co-supervised Imperial undergraduate iGEM teams since 2006.